Competing interests
TD
EVENTS, BREAST
MS has received personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche, and SeaGen, His institution has received research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, MS has a patent for EP 2390370 B1 and a patent for EP 2951317 B1 issued. TD serves on advisory boards of Novartis and IOMEDICO. NH has received personal fees for lectures and/or consulting from Amgen, AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, and Seagen. CT has received support for the following: the present manuscript from Sanofi-Aventis, Martin Luther University (NBL3 FKZ # 15/29 and 17/37), American Diagnostica, and BIOMED (BMH4—98 – 9418); grants or contracts from AGO-B Breast Study Group e.V.; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Gilead, Lilly, MSD, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Sanofi-Aventis, Roche, and Vifor; support for attending meetings and/or travel from Astra Zeneca, Celgene, Daiichi Sankyo, Novartis, Pfizer, Roche, Sanofi-Aventis; participation on a Data Safety Monitoring Board or Advisory Board for Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Hexal, Lilly, MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Sanofi-Aventis, Seagen, Roche, and Vifor; leadership or fiduciary role in other board, society, committee or advocacy group with AGO – Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Breast Committee, Brustkrebs Deutschland e.V., AGO-B Breast Study Group e.V., German Breast Group, and ABC Lisbon.